Keyphrases
Multiple Myeloma
91%
Chemotherapy
68%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
57%
Cisplatin
57%
Chronic Myeloid Leukemia
56%
Human Pluripotent Stem Cells (hPSCs)
53%
Induced Pluripotent Stem Cells (iPSCs)
50%
Overall Survival
49%
Stem Cell Lines
44%
Leucovorin
41%
South Korea
38%
Diffuse Large B-cell Lymphoma (DLBCL)
37%
Human Placenta
37%
Bortezomib
36%
Acute Myeloid Leukemia
35%
Newly Diagnosed
34%
5-fluorouracil (5-FU)
34%
CD34+
32%
Multiple Myeloma Patients
32%
Natural Killer T-cell Lymphoma
31%
Human Mesenchymal Stem Cells (hMSCs)
31%
Treatment Outcome
31%
Epirubicin
31%
Myelodysplastic Syndrome
30%
Extranodal
29%
Lymphoma Patients
28%
Neutropenia
28%
Confidence Interval
28%
Leukemia Patients
26%
Combination Chemotherapy
26%
Bone Marrow
26%
Phase II Study
26%
Adult Patients
26%
Mesenchymal Stem Cells
26%
Anemia
24%
Programmed Death-ligand 1 (PD-L1)
23%
Stem Cells
23%
Risk Factors
22%
Imatinib Mesylate
22%
Platelet Count
22%
Lymphoma
22%
Cell-conditioned Medium
21%
Placenta Cells
21%
Human Embryonic Stem Cells (hESCs)
21%
Etoposide
20%
Overall Response Rate
20%
Prognostic Value
20%
Mammalian Target of Rapamycin (mTOR)
19%
Complete Response
19%
Progression-free Survival
19%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Multiple Myeloma
62%
Cisplatin
62%
Overall Survival
44%
Folinic Acid
41%
Chronic Myeloid Leukemia
41%
Disease
39%
Acute Myeloid Leukemia
37%
Epirubicin
31%
Bortezomib
31%
Myelodysplastic Syndrome
29%
Malignant Neoplasm
29%
Neutropenia
26%
Fluorouracil
24%
Diffuse Large B Cell Lymphoma
24%
Imatinib
23%
Neoplasm
21%
Etoposide
20%
NK T Cell Lymphoma
20%
Abdominal Cancer
19%
Stomach Carcinoma
19%
Febrile Neutropenia
18%
Progression Free Survival
18%
Cyclophosphamide
18%
Cohort Study
17%
Anthracycline
17%
Aplastic Anemia
17%
Fibroblast Growth Factor 2
17%
Remission
15%
Nonhodgkin Lymphoma
14%
Receptor
14%
Anemia
14%
Cytarabine
14%
Ifosfamide
13%
Dexamethasone
13%
Granulocyte Colony Stimulating Factor
13%
Survival Rate
13%
Decitabine
12%
Reactive Oxygen Metabolite
12%
Nilotinib
11%
Idiopathic Thrombocytopenic Purpura
11%
Phase II Trials
11%
Acute Lymphoblastic Leukemia
11%
Azacitidine
11%
Promyelocytic Leukemia
11%
Paroxysmal Nocturnal Hemoglobinuria
11%
Eculizumab
11%
Liver Cell Carcinoma
11%
Paclitaxel
11%
Breast Carcinoma
11%
Medicine and Dentistry
Multiple Myeloma
86%
Chemotherapy
60%
Overall Survival
50%
NK T Cell Lymphoma
29%
Stem Cell
28%
Placenta
27%
Platelet
25%
Disease
25%
Abdominal Cancer
24%
Autologous Stem Cell Transplantation
24%
Vasculotropin
23%
Aplastic Anemia
23%
Chronic Myelogenous Leukemia
23%
Induced Pluripotent Stem Cell
23%
Hematopoietic Cell
23%
Progression Free Survival
20%
Pluripotent Stem Cell Line
20%
Acute Myeloid Leukemia
19%
Bortezomib
19%
Diffuse Large B-Cell Lymphoma
18%
Prognostic Factor
18%
Cytomegalovirus
17%
Folinic Acid
17%
Leukemia
17%
Human Pluripotent Stem Cell
17%
Neoplasm
16%
Myeloma
15%
Immunoglobulin Producing Cell
15%
Anemia
15%
Fibroblast Growth Factor 2
14%
Mesenchymal Stem Cell
14%
Long Term Survival
13%
Biological Marker
13%
Non-Hodgkin Lymphoma
13%
Survival Rate
13%
Myelodysplastic Syndrome
13%
Leukemia Cell
13%
Risk Stratification
13%
Feeder Cell
12%
Allogeneic Hematopoietic Stem Cell Transplantation
12%
Messenger RNA
12%
Reactive Oxygen Species
12%
Hematopoietic Stem Cell Transplantation
12%
Multivariate Analysis
12%
Human Embryonic Stem Cell
11%
Nilotinib
11%
Acute Promyelocytic Leukemia
11%
Fluorouracil
11%
Receptor
11%
Observational Study
11%